ARKG 📈 ARK Genomic Revolution - Overview
Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US00214Q3020 • Health
ARKG: Genomics, Gene, Editing, DNA, Sequencing, Diagnostics, Therapeutics
The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified. ‣ Company URL: http://www.ark-funds.com ‣ Domicile: United States
Additional Sources for ARKG ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ARKG ETF Overview
| Market Cap in USD | 1,240m |
| Category | Health |
| TER | 0.75% |
| IPO / Inception | 2014-10-31 |
ARKG ETF Ratings
| Growth 5y | -51.3% |
| Fundamental | - |
| Dividend | 13.6% |
| Rel. Strength Industry | -187 |
| Analysts | - |
| Fair Price Momentum | 19.78 USD |
| Fair Price DCF | - |
ARKG Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 45.3% |
ARKG Growth Ratios
| Growth Correlation 3m | 7.1% |
| Growth Correlation 12m | -64.6% |
| Growth Correlation 5y | -76.5% |
| CAGR 5y | -7.38% |
| CAGR/Mean DD 5y | -0.15 |
| Sharpe Ratio 12m | -0.73 |
| Alpha | -64.04 |
| Beta | 1.48 |
| Volatility | 52.96% |
| Current Volume | 6866.8k |
| Average Volume 20d | 2953.5k |
What is the price of ARKG stocks?
As of December 22, 2024, the stock is trading at USD 23.68 with a total of 6,866,763 shares traded.
Over the past week, the price has changed by -4.17%, over one month by +1.37%, over three months by -9.79% and over the past year by -23.86%.
As of December 22, 2024, the stock is trading at USD 23.68 with a total of 6,866,763 shares traded.
Over the past week, the price has changed by -4.17%, over one month by +1.37%, over three months by -9.79% and over the past year by -23.86%.
Is ARK Genomic Revolution a good stock to buy?
No, based on ValueRay Analyses, ARK Genomic Revolution (BATS:ARKG) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -51.29 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARKG as of December 2024 is 19.78. This means that ARKG is currently overvalued and has a potential downside of -16.47%.
No, based on ValueRay Analyses, ARK Genomic Revolution (BATS:ARKG) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -51.29 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARKG as of December 2024 is 19.78. This means that ARKG is currently overvalued and has a potential downside of -16.47%.
Is ARKG a buy, sell or hold?
ARK Genomic Revolution has no consensus analysts rating.
ARK Genomic Revolution has no consensus analysts rating.
What are the forecast for ARKG stock price target?
According to ValueRays Forecast Model, ARKG ARK Genomic Revolution will be worth about 22.3 in December 2025. The stock is currently trading at 23.68. This means that the stock has a potential downside of -5.7%.
According to ValueRays Forecast Model, ARKG ARK Genomic Revolution will be worth about 22.3 in December 2025. The stock is currently trading at 23.68. This means that the stock has a potential downside of -5.7%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 22.3 | -5.7% |